Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
10 2020
Historique:
received: 26 04 2020
revised: 30 06 2020
accepted: 02 07 2020
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 23 3 2021
Statut: ppublish

Résumé

To systematically investigate the association of environmental risk factors and prodromal features with incident Parkinson's disease (PD) diagnosis and the interaction of genetic risk with these factors. To evaluate whether existing risk prediction algorithms are improved by the inclusion of genetic risk scores. We identified individuals with an incident diagnosis of PD (n=1276) and controls (n=500 406) in UK Biobank. We determined the association of risk factors with incident PD using adjusted logistic regression models. We constructed polygenic risk scores (PRSs) using external weights and selected the best PRS from a subset of the cohort (30%). The PRS was used in a separate testing set (70%) to examine gene-environment interactions and compare predictive models for PD. Strong evidence of association (false discovery rate <0.05) was found between PD and a positive family history of PD, a positive family history of dementia, non-smoking, low alcohol consumption, depression, daytime somnolence, epilepsy and earlier menarche. Individuals with the highest 10% of PRSs had increased risk of PD (OR 3.37, 95% CI 2.41 to 4.70) compared with the lowest risk decile. A higher PRS was associated with earlier age at PD diagnosis and inclusion of the PRS in the PREDICT-PD algorithm led to a modest improvement in model performance. We found evidence of an interaction between the PRS and diabetes. Here, we used UK Biobank data to reproduce several well-known associations with PD, to demonstrate the validity of a PRS and to demonstrate a novel gene-environment interaction, whereby the effect of diabetes on PD risk appears to depend on background genetic risk for PD.

Identifiants

pubmed: 32934108
pii: jnnp-2020-323646
doi: 10.1136/jnnp-2020-323646
pmc: PMC7509524
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1046-1054

Subventions

Organisme : Parkinson's UK
ID : F-1201
Pays : United Kingdom
Organisme : Parkinson's UK
ID : G-1606
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026004/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ Open. 2012 Nov 06;2(6):
pubmed: 23135536
J Med Genet. 2020 May;57(5):331-338
pubmed: 31784483
Ann N Y Acad Sci. 1989;561:12-28
pubmed: 2735671
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
Mov Disord. 2019 Apr;34(4):480-486
pubmed: 30735573
Ann Neurol. 1998 Aug;44(2):294-5
pubmed: 9708562
Front Neuroendocrinol. 2009 Jul;30(2):142-57
pubmed: 19410597
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):31-7
pubmed: 23828833
Int J Epidemiol. 2018 Feb 1;47(1):226-235
pubmed: 29040562
Parkinsonism Relat Disord. 2016 Nov;32:25-30
pubmed: 27545685
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Environ Res. 2016 Nov;151:713-720
pubmed: 27640071
Pharmacol Biochem Behav. 2004 Jul;78(3):513-22
pubmed: 15251260
Prog Neurobiol. 2011 Jun;94(1):1-19
pubmed: 21439347
Int J Epidemiol. 2007 Oct;36(5):1111-8
pubmed: 17726040
Mov Disord. 2006 Dec;21(12):2211-4
pubmed: 17029261
Cell Tissue Res. 2004 Oct;318(1):121-34
pubmed: 15338272
Clin Chem. 2019 May;65(5):609-611
pubmed: 30808642
NPJ Parkinsons Dis. 2019 Mar 27;5:4
pubmed: 30937360
Mov Disord. 2017 Feb;32(2):219-226
pubmed: 28090684
Front Neuroendocrinol. 2014 Aug;35(3):370-84
pubmed: 24607323
Mov Disord. 2019 Jun;34(6):866-875
pubmed: 30957308
Mov Disord. 2001 Sep;16(5):830-7
pubmed: 11746612
Rev Endocr Metab Disord. 2016 Jun;17(2):221-40
pubmed: 27287364
Genet Med. 2019 Aug;21(8):1705-1707
pubmed: 30635622
Nat Genet. 2017 Jun;49(6):834-841
pubmed: 28436984
Scand J Rheumatol. 2004;33(2):73-81
pubmed: 15163107
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Mov Disord. 2012 Nov;27(13):1652-8
pubmed: 23045187
J Sex Med. 2018 Apr;15(4):430-457
pubmed: 29550461
Lancet Neurol. 2015 Oct;14(10):1002-9
pubmed: 26271532
Hum Mol Genet. 2019 Nov 21;28(R2):R133-R142
pubmed: 31363735
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
Mov Disord. 2018 Mar;33(3):405-413
pubmed: 29436728
Acta Neurol Scand. 2015 Jun;131(6):411-6
pubmed: 25399742
JAMA. 2020 Feb 18;323(7):636-645
pubmed: 32068818
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Ann Neurol. 2012 Dec;72(6):893-901
pubmed: 23071076
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
PLoS Genet. 2011 Aug;7(8):e1002237
pubmed: 21876681
Exp Neurol. 2014 Sep;259:44-56
pubmed: 24681088
Parkinsonism Relat Disord. 2016 Aug;29:54-9
pubmed: 27269966
Mov Disord. 2019 Oct;34(10):1464-1470
pubmed: 31412427

Auteurs

Benjamin Meir Jacobs (BM)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK.

Daniel Belete (D)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK.

Jonathan Bestwick (J)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK.

Cornelis Blauwendraat (C)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Sara Bandres-Ciga (S)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Karl Heilbron (K)

23andMe, Mountain View, California, USA.

Ruth Dobson (R)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK.

Mike A Nalls (MA)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Andrew Singleton (A)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

John Hardy (J)

Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.

Gavin Giovannoni (G)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK.
Centre for Neuroscience and Trauma, Barts and The London School of Medicine and Dentistry, Blizard Institute, London, UK.

Andrew John Lees (AJ)

Reta Lila Weston Institute of Neurological Studies and Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.

Anette-Eleonore Schrag (AE)

Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.

Alastair J Noyce (AJ)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK a.noyce@qmul.ac.uk.
Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH